Your cart is currently empty!
8 Results
$1.7M NIH SBIR Phase II Grant Awarded to AlphaThera for Development of ADCs to target Pancreatic Cancer
AlphaThera was awarded an SBIR Phase II grant by the NIH/NCI to further development of ADCs generated by proximity-based sortase-mediated ligation.
Supplemental $50,000 NIH TABA funding awarded to AlphaThera to support scaled commercialization of Site-specific Antibody Labeling Technology
The TABA supplemental funding will go directly towards supporting scaled commercialization activities of AlphaThera’s site-specific antibody labeling technology.
AlphaThera Awarded $667,000 SBIR Phase II Grant Extension for COVID-19 Detection Products
AlphaThera was awarded a grant to research & commercialize conjugation technologies that will assist in scale-up of COVID-19 serological assays to meet demand for daily testing.
NIH Grant Awarded to AlphaThera for Targeted Degradation of Cytosolic Proteins
AlphaThera was awarded an NIH Grant for research into Trim21-mediated degradation of antibody-targeted cytosolic proteins.
NIH Grant Awarded to AlphaThera for Antibody-MNase Conjugation
AlphaThera was awarded an NHI/NHLBI Grant to fund research for Photoreactive Antibody-Binding Domain-Microccocal Nuclease Conjugates ((pAbBD)-MNase).
NIH Phase II Grant to AlphaThera for Antibody Site-Specific Immobilization & Labeling
AlphaThera was awarded an NIH Phase II Grant for continued research into site-specific labeling and immobilization of antibodies for immunoassays.
NIH Grant Awarded to AlphaThera for Site-Specific ADCs by PBSL
AlphaThera awarded a grant by the NIH/NCI to fund research for Site-specific Antibody-Drug Conjugates by proximity-based sortase ligation.
NIH Grant Awarded to AlphaThera for Site-Specific Antibody Immobilization for Immunoassays Grant Award
AlphaThera was awarded an NIH/NIBIB Grant to fund research for designing Tools for Site-Specific Antibody Immobilization for Immunoassays.
5 Results
AlphaThera relocates to accommodate the company’s rapid expansion
AlphaThera have announced their relocation to a new larger laboratory and office space within the Pennovation Works Lab Building at the University of Pennsylvania.
AlphaThera Interview: Penn Center for Innovation interviews co-founder Dr. Andrew Tsourkas
AlphaThera’s co-founder, Dr. Andrew Tsourkas, was featured in a speaker event “Moving Ideas to Market: A Discussion with Entrepreneurs & Researchers” hosted by Penn Center for Innovation
AlphaThera in the News: oYo-Link™ Oligo Product Spotlight with Pennovation Center
Pennovation Works featured a product spotlight for AlphaThera’s oYo-Link™ Oligo Custom conjugation product.
AlphaThera Interview: Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas
Joe Fetterman of Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas about his backstory & path toward founding AlphaThera.
AlphaThera in the News: The Daily Pennsylvanian
UPenn’s prominent independent newspaper, the Daily Pennsylvanian, featured an article about AlphaThera’s recent COVID-19 grant award.
4 Results
Columbia Biosciences and AlphaThera partner to develop range of Site-Specific Fluorescent Protein Labeling Reagents
The partnership will provide the life science market with an innovative conjugation chemistry for antibody labeling.
Expansion of AlphaThera’s Distributor Network supports worldwide delivery of oYo-Link Antibody Labeling Technology
AlphaThera has announced the further expansion of its distributor network as interest in their oYo-Link Site Specific Antibody Labeling Technology continues to grow on an international scale.
oYo-Link® Products Now Available to Purchase through Quartzy
AlphaThera has teamed up with Quartzy to make their oYo-Link Antibody labeling products conveniently available to researchers for purchase.
Funakoshi Co., Ltd. Announced as AlphaThera’s Distribution Partner in Japan
AlphaThera has announced a distribution agreement with Funakoshi Co., Ltd. to deliver oYo-Link® Antibody labeling products to researchers in Japan.
5 Results
Columbia Biosciences and AlphaThera partner to develop range of Site-Specific Fluorescent Protein Labeling Reagents
The partnership will provide the life science market with an innovative conjugation chemistry for antibody labeling.
AlphaThera announces the launch of oYo-Capture™ Magnetic Beads
For the efficient removal of free oYo-Link® post conjugation AlphaThera has announced the launch of oYo-Capture™ Magnetic Beads, providing researchers with an efficient method of removing free oYo-Link® reagents post antibody conjugation to ensure low background in high sensitivity assays. AlphaThera is well known within the life science research community for their oYo-Link® antibody labeling […]
AlphaThera launches oYo-Link® Horseradish Peroxidase (HRP)
AlphaThera has announced the launch of oYo-Link® Horseradish Peroxidase (HRP), the latest addition to their range of site-specific antibody labeling reagents. The oYo-Link antibody-HRP labeling technology will enable the rapid production of highly uniform primary antibody conjugates in under two hours, and with only 30 seconds hands-on time.
AlphaThera Expand Their Range of oYo-Link Antibody-Drug Conjugate Reagents
AlphaThera have announced the addition of DM4 to their range of oYo-Link® Antibody-Drug Conjugation Reagents which also includes VcMMAE, VcMMAF and DM1.
AlphaThera Launches oYo-Link® Epitope Tag for Enhanced Multiplexing Capability
AlphaThera has announced the launch of oYo-Link® Epitope Tag, the latest addition to their range of site-specific antibody labeling reagents.
4 Results
AlphaThera Highlighted in Nature Methods Article: “How single-cell multi-omics builds relationships”
Dr. Andrew Tsourkas and Dr. Feifan Yu interview about oYo-Link Oligo technology and its potential within the field of multi-omic single-cell analysis.
AlphaThera & Penn Researchers’ Publication: Efficient native IgG labeling for ADC Production
AlphaThera members & Penn researchers worked to publish a high-impact publication in Bioconjugate Chemistry titled “Efficient Labeling of Native Human IgG by Proximity-Based Sortase-Mediated Isopeptide Ligation”.
Publication Feature: “Targeting cartilage EGFR pathway for osteoarthritis treatment” Science Translational Medicine
Read how a research team used AlphaThera’s site-specific bioconjugation technique to seed nanoparticles with a TGFa payload.
AlphaThera in the News: Atlas of Science
A layman’s summary of AlphaThera’s LASIC site-specific Antibody labeling technology was published by the Atlas of Science.